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Abstract
Extracellular vesicles (EVs) are membrane-surrounded structures that transmit biologically important molecules from the 
releasing to target cells, thus providing a novel intercellular communication mechanism. Since EVs carry their cargo in a 
protected form and their secretion is generally increased in tumorigenesis, EVs hold a great potential for early cancer diag-
nosis. By 3D culturing, we provide evidence that colorectal cancer (CRC) patient-derived organoids, representing a state-
of-the-art established and essential approach for studying human CRC, is a suitable model for EV analysis. When testing the 
effects of major factors promoting CRC progression on EV release in the organoid model, we observed that Apc mutation, 
leading to uncontrolled Wnt activation and thus to tumorigenesis in the vast majority in CRC patients, critically induces EV 
release by activating the Wnt pathway. Furthermore, the extracellular matrix component collagen, known to accumulate in 
tumorigenesis, enhances EV secretion as well. Importantly, we show that fibroblast-derived EVs induce colony formation 
of CRC organoid cells under hypoxia. In contrast, there was no major effect of tumor cell-derived EVs on the activation 
of fibroblasts. Collectively, our results with CRC and Apc-mutant adenoma organoids identify Apc mutation and collagen 
deposition as critical factors for increasing EV release from tumors. Furthermore, we provide evidence that stromal fibroblast-
derived EVs contribute to tumorigenesis under unfavorable conditions in CRC.
Keywords Exosome · Adenoma · Cancer patient-derived organoid · Stroma · Tumor · Collagen
Introduction
Colorectal cancer (CRC) is one of the most frequent causes 
of cancer-related death in the Western countries with a life-
time risk of approximately 5–6% [1]. In the large proportion 
of patients, APC inactivation is a central initializing muta-
tion in CRC tumorigenesis. This results in the continuous 
activation of the Wnt pathway, which leads to increased cell 
proliferation and loss of cell differentiation by intestinal 
epithelial cells. Some of these adenomas progress then to 
invasive lesions (carcinomas) by the accumulation of further 
mutations [2, 3]. In addition, changes in the extracellular 
matrix composition, such as the accumulation of collagen 
fibers [4], and signals from stromal cells function as major 
drivers in CRC tumor progression and metastasis formation 
[5].
Extracellular vesicles (EVs) are membrane-surrounded 
structures that represent a novel way of intercellular com-
munication by delivering biologically important molecules, 
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such as miRNAs, proteins, and lipids from the releasing to 
the target cells. EVs are heterogeneous considering their bio-
genesis, size, molecular cargo, specific markers, and func-
tions [6–9]. Exosomes are EVs (30–100 nm) of endosomal 
origin, derived from the multi-vesicular bodies (MVB) 
and released from cells upon fusion of the MVBs with the 
plasma membrane. Microvesicles (MVs) are shed directly 
from the plasma membrane and the larger apoptotic bodies 
(1–5 µm) are released by apoptotic cells [10]. Since EVs are 
present in body fluids, they may hold a great promise in early 
cancer diagnosis. This assumption is based on the fact that 
tumor cells release EVs at a higher level compared to nor-
mal cells [11] and that cancer cell-derived EVs carry tumor-
specific molecules as cargo in a membrane-surrounded, pro-
tected milieu. However, EV production and their molecular 
composition are highly dependent on the culture conditions, 
isolation methods, and external factors critically influencing 
both parameters [12]. Most of the published works focusing 
on EVs have so far used traditional 2D cell cultures in CRC. 
Unfortunately, the classical 2D tumor cell lines that have 
been cultured for a long time are derived from a limited cell 
population of cancer patients, and are highly selected upon 
setting up the 2D cultures. Thus, EV studies need a model 
system that better represents the in vivo situation in tumors. 
Furthermore, successful EV-based diagnostics critically 
depends on the amount of tumor-derived EVs in the body 
fluids. However, factors influencing EV production in CRC 
tumor cells are poorly characterized as yet.
The recently developed 3D organoid technology main-
tains the cellular and genetic heterogeneity of in vivo tis-
sues and has proved to be so far the best ex vivo model 
of human cancers [13, 14]. By now, organoids have been 
successfully cultured from many mouse and human healthy 
and cancer tissues, including pancreas [15], small intestine 
[16], colon [17], liver [18], etc. under well-defined specific 
culture conditions. In our study, we provide evidence that the 
3D organoid technology is suitable to study the production 
and functions of EVs in CRC. We prove that enrichment 
of extracellular matrix (ECM) in collagen type I and the 
Wnt pathway activating Apc mutation critically modify EV 
release by intestinal tumor organoids. Importantly, while we 
found no evidence of stromal fibroblast activation by cancer 
cell-derived EVs, fibroblast EVs increased the number of 




HCT116, SW620, and HT29 CRC cell lines were a kind 
gift from Prof. Kari Alitalo, University of Helsinki, Finland. 
SW1222 cells and normal human colon fibroblasts (ATCC-
1459) were from ECACC and ATCC, respectively. Thp-1 
cells were from ATCC. Cells were cultured in DMEM high 
glucose (Gibco) supplemented with 10% FCS (Gibco), 
cyprofloxacine, antibiotic/antimycotic mix, and glutamine 
(Sigma). Cells were tested for mycoplasma contamination 
with Hoechst staining and only negative cultures were used 
in our experiments. Two days before EV collection, cells 
were washed with PBS three times and they were further 
cultured in either medium without FBS or containing 2.5% 
EV-free FBS. EV-free FBS was prepared by overnight ultra-
centrifugation at 100,000g or purchased from Gibco (exo-
some depleted One-Shot FBS). For 3D cultures, cells were 
treated with TrypLE (Gibco), embedded into Matrigel with 
5000–10,000 cells depending on the cell line and cultured 
for 12-14 days.
Producing and culturing Apc‑mutant mouse 
organoids
The Pest County Government Office (Hungary) as the vet-
erinary authority approved the maintenance and experi-
ments with mice. Normal intestinal crypts from C57Bl/6J 
(Jackson Laboratory, 000664) or UBI-GFP mice (Jackson 
Laboratory, 004353) were isolated according to previ-
ously published methods [16]. Approximately 500 crypts 
were embedded into growth factor-reduced, phenol red-free 
Matrigel (Corning, 20 µl/well in 48-well plates) and cul-
tured in small intestinal medium (SIM): advanced DMEM/
F12 medium (Gibco) containing B27 and N2 supplements 
(Gibco), 10 mM HEPES (Sigma), 1 µM N-acetyl cysteine 
(Sigma), glutamine, penicillin/streptomycin, 100 ng/ml nog-
gin (Peprotech), 50 ng/ml EGF (Peprotech), and 500 ng/ml 
mouse R-Spondin1 (R&D Systems). Crypts were mechani-
cally split by vigorous pipetting and embedded into new 
Matrigel in every 4-5 days. In some experiments, organoids 
were added the GSK-3 inhibitor CHIR99021 dissolved in 
DMSO (3 µM, Tocris), 1% DMSO as control or 100 ng/
ml murine Wnt3a (Peprotech) for 3 days before processing 
samples for immunostaining. In these studies, the EVs in the 
supernatants were detected by anti-CD81-coated beads after 
3 days (see below).
sgRNA sequence for mouse Apc was published previ-
ously (sgRNA4, [19]) and cloned into lentiCRISPR v2 
(Addgene 52961) into the BsmBI restriction sites according 
to Addgene’s instructions. Apc-mutant organoids were pro-
duced according to the previously published protocol [19] 
with some modifications. Briefly, mouse organoids were cul-
tured in SIM with the GSK-3 inhibitor CHIR99021 (3 µM, 
Tocris) for 2 days, and organoids were then treated with 
TrypLE to obtain single cells. Cells were resuspended in 
SIM + CHIR99021 + 10 µg/ml Y-27632 (Rho-kinase inhibi-
tor, Sigma) and plated in 48-well plate in 400 µl. They were 
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transfected with JetPEI (Polyplus Transfection) using 1 µg 
plasmid and 2 µl JetPEI Reagent according to the manufac-
turer’s recommendations. Cells were centrifuged at 600 g at 
RT for 1 h and then further incubated for 4 h at 37 °C. After 
washing, cells were plated in Matrigel with SIM containing 
Y-27632. The Rho-kinase inhibitor, R-Spondin1, EGF, and 
noggin were removed 3 days after transfection and organoids 
with Apc mutation were selected for > 6 days without growth 
factors.
Human organoid cultures
The Medical Research Council of Hungary approved all 
experiments involving human samples and informed con-
sent was obtained from the patients. Tissue biopsies from 
patients were processed according to previously published 
methods [17, 20]. The isolated tissue pieces were embed-
ded into Matrigel and cultured in human organoid medium 
(HOM) containing advanced DMEM/F12 with N2 and B27 
supplements, 10 mM HEPES, 1 mM N-Acetyl-Cysteine, glu-
tamine, penicillin/streptomycin, 500 nM A83-01 (Sigma), 10 
uM SB202190-Monohydrochloride (Sigma), and 50 ng/ml 
EGF. In addition, the Rho-kinase inhibitor Y27632 (Sigma) 
was added after splitting and it was removed from medium 
at day 2. Organoids were isolated from Matrigel in every 
4–6 days by centrifugation at 300 g for 5 min, mechanically 
disrupted, treated with TrypLE for 3–5 min and then after 
washing embedded into Matrigel again.
In some experiments, cell line-derived colonies or orga-
noids were centrifuged at 300 g for 5 min, the Matrigel was 
removed and after washing steps with PBS, colonies or 
organoids were further cultured in 24-well suspension plates 
(Eppendorf). Hypoxia was generated with AnaeroGen 2.5L 
bags (Thermo Scientific). Hypoxic condition was checked by 
anaerobic indicator (Thermo Scientific, BR0055B). When 
testing the effect of EVs on fibroblasts, CRC organoids were 
cultured for 2 days and EVs from about 1 ×  106 cells were 
added to 1 ×  105 fibroblasts in 500 µl EV-free medium. In 
case of microarray experiments, EVs from 1.5 ×  106 cells 
were harvested and 2 ×  106 fibroblasts were used.
Collagen‑based organoid cultures
Organoids were centrifuged, washed with PBS twice, and 
embedded into collagen type I (from rat tail, Ibidi). To cre-
ate 100 µl collagen matrix, 60 µl water, 10 µl 10 × MEM 
(Gibco), and 30 µl collagen I were mixed and the pH was set 
to 7.2 with 1 M NaOH. Collagen was then added to the orga-
noids and they were cultured in droplets in 48-well plates 
in HOM. When removing cells, collagenase II (Sigma) was 
added to the medium for 30 min at 37 °C and cells were then 
centrifuged at 300 g for 5 min.
qNano measurements
Culture supernatants were harvested after 48 h, centrifuged 
at 300g for 5 min, and the supernatant was then pelleted 
again at 2000 g for 20 min to remove cells and cell debris. 
Supernatant was applied to qNano (Izon) analysis. In case of 
SW1222 colonies, supernatants were directly measured after 
centrifugation at 300 g for 5 min on membranes with pore 
size of 100, 400, 800, or 2000 nm. Minimum 500 data points 
were collected or, when not possible, samples were meas-
ured for 5 min. Calibration beads CPC100B or CPC400G 
(Izon) were suspended in the same culture media.
Human EV detection by anti‑CD63 
or anti‑CD81‑coated beads
Culture supernatants were collected, and after centrifug-
ing at 300 g for 5 min and 2000 g for 20 min, EVs were 
bound to antibody-coated beads that had been blocked with 
0.1% BSA (Sigma) in PBS for 30 min. According to our 
previous experiments, 20 µl or 6 µl of anti-CD63-coated 
beads (Thermo Fisher, 10606D) or anti-CD81-coated beads 
(Thermo Fisher, 10616D) were added to 200 µl superna-
tant, respectively. After overnight rotation at 4 °C, beads 
were magnetically separated, washed with Annexin bind-
ing buffer (BD Biosciences) three times and beads were 
labelled for 20 min. 10,000 beads were then measured on a 
FACSCalibur (BD) instrument. FITC-anti-CD81 (A15753, 
Molecular Probes), PE-anti-CD63 (SAB47000218, Sigma), 
and FITC Annexin V (SAB4700218, Sony) or APC Annexin 
V (Immunotools, 31490016) were used for detection (2 µl/
sample). In all experiments, cells were counted with Burker 
chamber and results were normalized to cell number.
Mouse EV detection by anti‑CD81‑coated beads
Anti-CD81 antibody (MA180209, Thermo Scientific) was 
bound to magnetic beads by Dynabeads Antibody Coupling 
Kit (Invitrogen) according to the manufacturer’s instruc-
tions, coupling 10 µl antibody to 2 mg beads. 2 µl of the anti-
body-coated beads was then applied to 200 µl supernatant 
similar to the human EV detection. EVs bound to beads were 
detected by PE-anti-CD81 antibody (MA517941, Thermo 
Scientific) and the results were normalized to cell number.
Detecting PTK7 by flow cytometry
CRC organoids were removed from Matrigel and treated 
with TryPLE (Gibco) for 5–10 min to obtain single cells. 
Cells were then labelled with APC anti-PTK7 (Miltenyi 
Biotech) for 20 min and then centrifuged at 300 g for 5 min. 
10,000 cells were measured with a flow cytometer (FACS 
Calibur, BD).
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EV detection by flow cytometry
EV detection by flow cytometry was carried out according 
to [21] with minor modifications. Briefly, cells and cell frag-
ments were removed from cell culture supernatant by serial 
centrifugation at 300 g for 5 min and 2000 g for 20 min. 
50 µl of supernatant was labelled with FITC Annexin V 
(Sony) for 30 min, and then, 200 µl Annexin Binding Buffer 
(BD Biosciences) was added. Large EVs were measured 
for 90 s, and then, samples were analyzed again after add-
ing 0.1% Triton X-100 that disrupts EVs. Absolute counts 
were calculated using Count Check Microbeads (Sysmex 
Partec GmbH, Germany). Large EV absolute number with 
flow cytometer (FACS Calibur, BD) was determined with 
the following formula:
Number of vesicles in sample = (detected EV events in the 
EV gate—Triton X-100 resistant events)/number of events 
in bead gate) × Absolute count of Count Check beads in the 
tube × sample dilution.
EV isolation
Cell or organoid culture supernatants were collected and 
serially centrifuged at 300 g for 5 min and 2000 g for 20 min. 
The supernatant was then further pelleted at 12,500 g for 
20 min to obtain the large EV fraction. Small EVs were iso-
lated with ultracentrifugation (UC) at 100,000g for 70 min 
at 4 °C. All EV fractions were washed with PBS and cen-
trifuged or ultracentrifuged once more before usage. The 
large and small EVs were combined in functional tests. For 
miRNA detection, EVs were separated by UC or by the addi-
tion of anti-CD63 (120 µl/2 ml supernatant) and anti-CD81 
coated beads (60 µl/2 ml supernatant) and EVs were lysed 
in Qiazol Lysis Reagent (Qiagen) after overnight incuba-
tion and washing steps with PBS (5 times). Alternatively, 
EV-derived total RNA was extracted with the ExoRNEasy 
Serum/Plasma Starter Kit (Qiagen) from 2 ml supernatant 
according to the manufacturer’s instruction.
Proteomics analysis of EVs
CRC organoids were cultured in 20 µl Matrigel droplets in 
200 µl HOM in 48-well plates and the supernatant was col-
lected every second day. Samples collected from the same 
CRC organoid line were combined and EVs were separated 
from a total of 23 ml supernatant with differential UC. As 
a control, organoid-free Matrigel droplets were applied. EV 
pellet was resuspended in 80 µl water and proteins were 
extracted using repeated freeze–thaw cycles followed by 
miniaturized tryptic digestion as previously described [22]. 
Before the tryptic digestion, protein concentration was deter-
mined by the Micro BCA Protein Assay Kit (Thermo Scien-
tific). Mass spectrometry of EV preparations was carried out 
according to [22]. Proteins present in the Matrigel controls 
were removed from organoid sample-derived lists of proteins 
and these lists were further analyzed.
Testing the effects of fibroblast‑derived EVs
Supernatant from fibroblasts (cultured in normoxia or 
hypoxia in HOM for 4 days) was collected, ultracentrifuged 
and the EV-containing pellet and EV-free supernatant were 
added to CRC organoid-derived cells. To produce CRC cells, 
CRC organoids were removed from Matrigel by centrifu-
gation at 300 g for 5 min, treated with TrypLE until they 
were dissociated into single cells and they were washed 
with PBS before embedding into 20 µl Matrigel in 48-well 
plates (Eppendorf). EVs from about 500,000 fibroblasts 
were added to the Matrigel droplets. Colonies were counted 
4–5 days after incubating in normoxia or hypoxia.
Liposome production and characterization
High purity hydrogenated soy phosphocholine (HSPC, NC-
21E, NOF Corporation, Japan) and cholesterol (C3045, 
Sigma) were used without further purification. Unilamellar 
liposome samples were prepared by the hydration and extru-
sion method. Briefly, 40 mg HSPC and 29 mg cholesterol 
were dissolved in 0.6 ml ethanol at 60 °C. 4 ml ultrapure 
water was added to the mixture and it was stirred for 10 min 
at 60  °C with a continuous nitrogen flow. The sample 
was then extruded ten times through polycarbonate filters 
(Nucleopore, Whatman Inc.) with 100 nm pore size using 
an LIPEX extruder (Northern Lipids Inc., Canada) at 60 °C. 
Finally, it was dialyzed against ultrapure water in a Slide-A-
Lyzer™ MINI Dialysis Device (Thermo Fisher Scientific) 
for 24 h to remove residual traces of ethanol.
The size distribution of the liposome sample was charac-
terized by dynamic light scattering (DLS). The DLS meas-
urement was performed using a W130i apparatus (Avid 
Nano Ltd., High Wycombe, UK) and using a low volume 
disposable cuvette (UVette, Eppendorf Austria GmbH). The 
liposomes had a mean diameter of 105 nm.
Transmission electron microscopy
After ultracentrifugation, the pellet was resuspended in 20 µl 
PBS and a 2 µl droplet was dried on a formfar-carbon coated 
300 mesh grid (Electron Microscopy Sciences, USA) for 
10 min. The EVs were then fixed with 4% glutaraldehyde 
for 10 min and the grid was washed with water three times. 
The EVs were stained with 2% phosphotungstic acid, they 
were allowed to dry at room temperature and imaged with 
a MORGAGNI 268D (FEI, The Netherlands) transmission 
electron microscope.
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Wound‑healing assay
Human colon fibroblasts (ATCC-1459) were cultured 
in 24-well plate until confluence. A scratch was created 
with a p200 pipette tip in the cell monolayer. Cells were 
washed 3× with PBS to remove cell debris and 250 µl fresh 
medium (DMEM high glucose with 2.5% EV-free FBS, 
antibiotic/antimycotic mix, and glutamine) and 250 µl cell-
culture supernatant after EV isolation (EV-free) was added 
to the cells. For the EV-treated cells, the EV pellet was 
resuspended in 20 µl PBS and added to the cells as well. 
Images were taken at 0, 12, 16, and 20 h with a Nikon Dia-
phot microscope. The cell-free areas were evaluated by the 
ImageJ software. In some experiments, EVs were isolated 
from CRC organoids cultured in hypoxia for 2 days.
Whole‑mount staining
Organoids were cultured in 4-well chamber slides (BD 
Biosciences), fixed in 4% PFA for 30 min, washed with 
PBS + 4% NaCl and blocked and permeabilized in block-
ing buffer (5% FBS, 0.2% BSA, 0.3% Triton X-100 in 
PBS) for 30 min. The following primary antibodies were 
applied at 4  °C overnight in blocking buffer: rat anti-
vimentin (MAB2105, R&D Systems), rabbit anti-lumican 
(ab168348, Abcam), rabbit anti-active caspase-3 (AF835, 
R&D Systems), rabbit anti-Ki67 (Abcam, ab16667), rabbit 
anti-mucin2 (Santa-Cruz Biotechnology, sc-15334). After 
washing in PBS containing 0.3% Triton X-100 and 4% 
NaCl and overnight incubation with the secondary anti-
bodies (Alexa Fluor 488 and 594, Thermo Fisher), the 
organoids were mounted in mounting medium contain-
ing DAPI (Thermo Fisher) and imaged with an Olympus 
FV500 confocal microscope.
RNA isolation and RNA measurements
RNA and total RNA with small RNAs were isolated with 
the RNEasy Micro Kit and miRNeasy Micro Kit (Qiagen), 
respectively, according to the manufacturer’s instructions 
in 15 µl water. In some experiments, EV-derived miR-
NAs were obtained using the ExoRNEasy Serum/Plasma 
Starter Kit (Qiagen). RNA concentration was determined 
by NanoDrop.
For miRNA measurements, 2 µl total RNA (including 
small RNA) was reverse transcribed with the  TaqMan® 
Advanced miRNA cDNA Synthesis Kit (Thermo Fisher) 
according to the manufacturer’s description. PCR reactions 
were then carried out with  TaqMan® Fast Advanced Mas-
ter Mix and  TaqMan® Advanced miRNA Assays (Thermo 
Fisher). A Ct value cutoff of 35 was considered as positive 
result and data are visualized as 35-Ct values. miRNAs and 
assay IDs are in Table S1.
For mRNA measurement, 0.5 µg total RNA isolated from 
organoids was reverse transcribed with the SensiFAST™ 
cDNA Synthesis Kit (Bioline). Quantitative PCR reactions 
using the SYBRGreen method were carried out with the Sen-
siFAST™  SYBR® Hi-ROX Kit (Bioline) on an ABI 7900HT 
Fast real-time PCR instrument in 384-well format in 5 µl 
volume. Results were calculated using the following proto-
col: relative expression level = 2−ΔCt, where ΔCt = Ct(gene 
of interest)—Ct(housekeeping gene). The primers used are 
listed in Table S1.
Sequencing
cDNA was amplified with Phusion High Fidelity DNA Poly-
merase (Thermo Fisher) with the following primers: p53: 
TGA AGC TCC CAG AAT GCC AG and CTT CAG GTG GCT 
GGA GTG AG (65 °C), KRAS: CCC AGG TGC GGG AGAGA 
and AGG CAT CAT CAA CAC CCT GT (65 °C). The DNA 
was then isolated from 2% agarose gel, purified by the Gel 
Purification Kit (Macherey–Nagel) and sequenced by the 
forward primers with Applied Biosystems 3500 Genetic 
Analyzer instrument (Life Technologies). Data were ana-
lyzed by the Chromas 2.6 software (Technelysium Pty Ltd).
Microarray experiments
RNA quality was determined with the Bioanalyzer Pico 
Chip (Agilent) and analyzed on Agilent 4 × 44 K human 
whole genome expression microarrays. Data were processed 
by the Feature Extraction Software 12.0.3.1 (Agilent) and 
then imported into Chipster (www.chips ter.csc.fi) and the 
standard Agilent one colour normalization method was 
applied. Preprocessing was carried out by filtering by stand-
ard deviation (percentage to filter out: 0.67, which is about 
1 SD). Genes with expression difference were listed using 
empirical Bayesian paired t test with no p value adjustment 
methods. The pre-filtered genes were used for hierarchical 
clustering using the Pearson distance method. The microar-
ray data have been submitted to the GEO database (www.
ncbi.nlm.nih.gov/geo/) under the series accession number 
GSE114979.
Gene set enrichment and survival analysis
The gene expression data set was transferred to the Gene 
Set Enrichment Analysis software (http://www.broad insti 
tute.org/gsea [23, 24] and the analysis was carried out with 
default parameters except that the “exclude smaller sets” 
was set to 20 and gene permutation was applied. We used 
a modified list of the kegg.v3.1.symbols gene set (http://
www.broad insti tute.org/gsea/msigd b) with the addition of 
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Wnt targets [25], intestinal stem cell-specific genes [26], and 
exosome biogenesis genes. FDR q value < 0.1 was regarded 
significant. The exosome biogenesis gene set was created 
based on published data and genes with proved function in 
MVB biogenesis and exosome secretion were selected. The 
gene set is shown in the Supplementary Information.
For survival analysis, the GSE17537 and GSE14333 data 
sets were used, both containing patient survival data as well. 
Expression levels were z-score transformed for all genes 
before carrying out Kaplan–Meier analysis and log rank test.
Statistical analysis
Student’s paired or unpaired t test, Mann–Whitney U test, 
one-way ANOVA, and Tukey post hoc test or Kruskal–Wal-
lis test with Dunn post hoc test were used with *p < 0.05, 
**p < 0.01, and ***p < 0.001 significance levels. For evalu-
ation, Microsoft Excel, SPSS version 25, and Sigma Plot 
softwares were used.
Results
CRC organoid‑derived EVs can be detected 
in cultures in 3D matrix
The SW1222 CRC cell line forms lumen-containing com-
plex large colonies (megacolonies) in 3D matrix, containing 
both undifferentiated and differentiated cancer cells, similar 
to the in vivo tumors [27, 28]. To set up 3D cultures for EV 
detection, we used both basement membrane extract (BME) 
and Matrigel as 3D matrices. Tunable resistive pulse sens-
ing (qNano) measurements, suitable for detecting particles 
with different sizes, showed that the background particle 
numbers of BME or Matrigel were negligible compared with 
3D colonies (Fig S1a, b). Furthermore, we observed a higher 
concentration of smaller particles compared to larger ones in 
the supernatant of SW1222 colonies when using membranes 
of different pore sizes (Fig. S1c). Interestingly, we found a 
modestly increased colony-forming efficiency of SW1222 
cells in Matrigel compared to BME (Fig. S1d), but there 
was no difference in particle production normalized to cell 
number (Fig. S1a). Importantly, SW1222 cells required EV-
free fetal bovine serum (FBS) in the medium to form 3D 
colonies (Fig. S1d).
To identify and assess EVs from cell-culture superna-
tants, we used anti-CD63 or anti-CD81-coated magnetic 
beads and detected EVs by fluorescently labelled anti-
CD63 or anti-CD81 antibodies and flow cytometry. CD63 
and CD81 are generally regarded as EV markers and plasma 
membrane-derived larger EVs can often be labelled by 
Annexin V. As published previously [29], we observed a 
correlation between the cell number and the percentage of 
positive beads in two cell lines (Fig. S1e, f), furthermore, 
between the cell number and the particle number as well 
(Fig. S1g), showing that the bead-based method can be used 
for the semi-quantitative measure of EVs. Since the cor-
relation between cell number and the positive beads was 
valid only above a threshold of cell number, we used similar 
cell numbers in all of our subsequent comparisons and we 
normalized all the results to cell number. Furthermore, we 
accepted experiments only when the sample with the low-
est percentage of positive beads did not have the lowest cell 
number among the samples. Importantly, EVs released by 
SW1222 cells bound only to anti-CD63-coated beads, but 
not to beads covered by streptavidin, thus confirming the 
specificity of the system (Fig. S1h).
Next, we used other CRC cell lines that form 3D colonies 
with different morphologies (Fig. S2a). In 2D cultures, we 
detected both CD63 +/Annexin V–EVs by the bead-based 
method and Annexin V + large EVs by flow cytometry in 
all cell lines from the supernatant (Fig. 1a, b). Similarly, 3D 
colonies in Matrigel or colonies removed from 3D matrix 
and further cultured in suspension plates produced CD63 +/
Annexin V–EVs (Fig. 1c, d). In a parallel experiment, we 
could detect CD81 + EVs as well (Fig. S2b, c). Interest-
ingly, however, comparing the two culture conditions, larger 
Annexin V + EVs were present at a higher amount in sus-
pension cultures compared to the 3D matrix-grown colo-
nies (Fig. 1e). In these experiments, we detected Annexin 
V + events that were sensitive to Triton X-100 lysis using the 
previously published, flow cytometry-based method [30]. 
Collectively, these results suggest that colony-derived larger 
EVs can be detected at a much higher level in suspension. 
However, this culture condition results in the increase of 
active caspase-3 + apoptotic cells (Fig. 1f), thus showing that 
suspension condition is not optimal for the colonies.
The 3D organoid technology represents a superior model 
system, since these organoids are directly derived from CRC 
patients (Fig. 2a, Table S2), and similar to tumors, the cel-
lular and genetic heterogeneity is a major hallmark of these 
organoids [31]. Importantly, all CRC patient-derived orga-
noids produced CD63 + and CD81 + EVs in 3D cultures 
(Fig. 2b) and the presence of EVs in organoid culture super-
natants was confirmed by qNano (Fig. 2c) and transmission 
electron microscopy as well (Fig. 2d).
We used three CRC patient-derived organoid lines 
(CRC1-3) in our further experiments. In CRC1-3, a sub-
population of the cells was highly positive for PTK7, a 
recently indentified marker for the stem-like cell population 
with high Wnt activity in CRC [32] (Fig. S2d). To inves-
tigate which pathways were mutant in these cultures, we 
tested their survival without R-Spondin1 or EGF or in the 
presence of nutlin-3 (see [33, 34]). Importantly, nutlin-3 
inhibits p53 binding to the ubiquitin ligase MDM2; thus, 
cells with normal p53 undergo apoptosis. As expected, all 
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Fig. 1  CD63 + EVs are released from 3D cultures. a Cells of the 
indicated cell lines were cultured 2D and EVs were captured by anti-
CD63-coated beads, detected either by anti-CD63 or by Annexin V 
and the percentage of positive beads was measured with flow cytom-
etry. In the left and middle panels, selected flow cytometric measure-
ments from SW1222 cells are shown. Right panel: quantification of 
flow cytometry results. b Detecting Annexin V + events in the EV 
gate from 2D culture supernatants. Note that the largest EVs, con-
taining apoptotic bodies, were removed by centrifugation before 
the measurements. In these experiments, EVs were directly meas-
ured by flow cytometry. (c–d)  Percentage of positive beads from 
colonies cultured 3D in Matrigel (c) or after Matrigel culturing, 
the colonies were maintained in suspension (d) for 48 h. e Number 
of Annexin V + events in the supernatant of SW1222 cells, derived 
from 3D cultures or colonies maintained in suspension after remov-
ing from Matrigel (flow cytometry). Left and middle panels: selected 
flow cytometric measurements from suspension cultures. Annexin 
V + events were determined before and after the addition of Triton 
X-100 (see “Materials and methods”). Right panel: quantification of 
samples with or without cells and before or after centrifugation at 
12,500 g for 20 min. Note that EVs are not detectable from the super-
natant after centrifugation (n = 3, t test). f Percentage of active cas-
pase-3 events in different culture conditions of SW1222 cells (flow 
cytometry, n = 3–5, t test). The percentage of positive beads was nor-
malized to cell number
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cultures grew when the Wnt-agonist R-Spondin1 was absent, 
but none of them survived in the absence of EGF and they 
were insensitive to nutlin-3 (Table S3). These results agree 
with our sequencing data for KRAS and TP53 (Table S3). 
Thus, all three organoid cultures contained a continuously 
active Wnt and a mutant p53 pathway, but the KRAS path-
way was not mutant.
CRC organoid‑derived EVs carry proteins 
and miRNAs
EVs are considered as transmission vehicles of proteins and 
miRNAs between cells. Our proteomic analysis of EVs from 
three CRC organoid lines showed that only about 45% of 
the detected proteins were present in all samples, highlight-
ing the large variance between individual patient-derived 
organoid samples (Fig S3a and Tables S4, S5). To prove 
that CRC organoid-derived EVs carry miRNA in our model 
system, we measured 14 miRNAs in EVs isolated with three 
different methods. Whereas miR-484 or miR34a-5p were 
detected only by a commercial EV RNA isolation kit, most 
other miRNAs were present both in case of this kit or differ-
ential ultracentrifugation, although at different amounts (Fig. 
S3b, c). Interestingly, when using antibody-coated beads, 
we could detect only 8 miRNAs out of the 14 measured 
(Fig. S3d) and this isolation method resulted in the lowest 
unspecific background. Thus, similar to previously published 
results from 2D cultures, CRC organoid-derived EVs carry 
proteins and miRNAs as cargo; however, the EV isolation 
method largely influences the detected profile and there is a 
high variation among samples.
The tumor promoting collagen I ECM protein 
induces EV release from CRC organoids
Having proved that organoids produce EVs in 3D matrices, 
we wanted to apply this system to find factors that influence 
EV release. Changes in the extracellular matrix composi-
tion, such as accumulation of collagen type I is critical in 
CRC progression [4] and the expression levels of COL1A1 
and COL1A2 genes are associated with decreased patient 
survival (Fig S4a). Oncomine database analysis of the 
TCGA data set indicated that CRC patients show an elevated 
COL1A1 and COL1A2 level compared to healthy controls 
(Fig S4b). Patient-derived CRC organoids started to invade 
ECM when cultured in collagen I with a parallel increase 
in the expression of the epithelial–mesenchymal transition 
(EMT) marker vimentin and an enhanced EV secretion at 
day 2 after plating (Fig. 3a, b). Importantly, at this time-
point, we could not see a massive apoptosis yet (Fig. 3c). 
Collectively, these data suggest that the ECM composition 
is critical for EV release in CRC tumorigenesis.
Apc mutation increases EV release from 3D 
organoids
It is widely accepted that EV secretion increases in tumors 
compared to normal tissues. However, whether this can be 
attributed to mutations is not yet known. Since CRC cells 
represent a late stage of tumorigenesis and carry a wide vari-
ety of mutations, we used a mouse model with well-defined 
genetic background. We introduced Apc mutation into wild-
type (WT) small intestinal organoids by CRISPR-Cas9 and 
we selected Apc-mutant organoids, representing the ade-
noma stage of intestinal tumors, without adding the external 
Wnt-agonist R-Spondin1. Since WT intestinal stem cells are 
strictly dependent on R-Spondin1, only Apc-mutant orga-
noids survive after 5 days under these conditions (Fig. 4a). 
Interestingly, we observed a massive increase in CD81 + EV 
secretion after Apc mutation (Fig. 4b). One possible expla-
nation for the increased EV release after Apc mutation is an 
elevated expression of genes involved in this process. Unfor-
tunately, no single gene is responsible for EV release and 
different EV pathways may operate in different cell types. 
Exosomes (EX) are specific EVs of endosomal origin with 
the best characterized routes of production and secretion 
among EV types. To test whether the EX route is respon-
sible for the enhanced EV secretion, we selected 39 genes 
Fig. 2  CRC patient organoid-derived EVs can be measured in 3D 
cultures. a Morphology of CRC patient-derived organoids (scale 
bars: 50  µm). b Percentage of EV-bound, anti-CD81 or anti-CD63-
coated beads, detected by anti-CD81 or anti-CD63, respectively. 
Supernatants  from 3D cultures without (Matrigel) or with organoids 
were processed after 48 h (flow cytometry, n = 3, t test). Positive bead 
percentage was normalized to 300,000 cells. c Size distribution and 
number of particles from five organoid cultures (qNano with 400 nm 
pore size). d Transmission electronmicroscopic image of CRC orga-
noid-derived EVs (arrows), isolated by differential ultracentrifugation
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with proved function in multi-vesicular body (MVB) forma-
tion and EX release (e.g., specific Rab proteins) (Table S6). 
This gene set was used in Gene Set Enrichment Analysis 
(GSEA) on publicly available expression data derived from 
organoid libraries (GSE74843) [35]. Importantly, these orga-
noid libraries contain only cells of epithelial origin, thus 
excluding stroma-derived signals. As expected, we observed 
a positive enrichment of the Wnt-target gene set and KEGG 
cell cycle genes in the human adenoma samples compared 
to normal organoids (Fig. S5a). However, the EX biogenesis 
gene set showed a negative enrichment (Fig. S5a). To rule 
out the possibility that the EX biogenesis gene set behaves 
differentially in humans and mice, we repeated our analysis 
on expression data sets derived from microdissected WT 
intestinal epithelial cells and Apc-mutant adenomas derived 
from mouse (GSE422). Again, we found no positive enrich-
ment of the EX biogenesis gene set in the adenoma samples 
(Fig. S5b), suggesting that the increased EV release after 
Apc mutation is not a consequence of the higher expression 
level of EX biogenesis genes in this system.
Apc mutation induces the Wnt pathway. To test whether 
Wnt pathway activation may lead to an enhanced EV release, 
WT intestinal organoids were treated with Wnt3a or the 
GSK-3 inhibitor CHIR99021, known activators of this sign-
aling pathway. Similar to Apc mutation, both Wnt3a and 
CHIR99021 resulted in an increased ratio of Ki67 + prolif-
erating and decreased percentage of Mucin-2 + Goblet cells, 
which was paralleled by a lower RNA level of Mucin-2 and 
the enterocyte marker Alpi, and an increase in the Wnt-
target stem cell marker Lgr5 (Fig. 4c–f). Importantly, both 
Wnt3a and CHIR99021 resulted in a massively elevated EV 
release from organoids, similar to Apc mutation (Fig. 4g), 
without an increased number of apoptotic cells (Fig. 4h). 
Collectively, these results strongly support the hypothesis 
that Apc mutation increases EV secretion via activating 
the Wnt pathway in the organoids. Furthermore, since Apc 
mutation is a very early event in intestinal tumorigenesis, 
our data suggest that increased EV release occurs already 
in the adenoma stage.
Fibroblast‑derived EVs increase the number 
of organoids under hypoxia
Since our data show that several factors induce EV release 
from adenoma and CRC cells, we then applied the organoid 
system to study the role of EVs in the tumor–stroma commu-
nication. First we tested the effect of CRC organoid-derived 
EVs after differential UC using commercially available nor-
mal human colon fibroblasts. We proved the difference in EV 
amount in the EV-enriched pellet and the EV-depleted super-
natant by anti-CD63 or anti-CD81-coated beads and flow 
cytometry (Fig. S6a). ATCC-1459 human colon fibroblast 
cells were treated with EV-enriched or EV-depleted medium 
prepared from supernatants of the 3D CRC organoids and 
microarray experiments were carried out. In this experimen-
tal setting, the effect of EVs was compared to the EV-free 
CRC-derived condition. As control, organoid-free Matrigel-
derived medium (pelleted and supernatant) was used. As 
expected, CRC-derived medium, independently of the EV 
content, resulted in an overall change in the gene expression 
of fibroblasts (Fig. S6b). Interestingly, CRC-derived EVs 
had no major effect on the transcriptional profile of fibro-
blasts and a small subset of genes (about 100 genes) showed 
only a modest (< twofold) expression change (Table S7). 
Fig. 3  Replacing Matrigel to collagen I results in an elevated EV 
release from CRC organoids. a Vimentin whole-mount immunostain-
ing of one of the CRC organoid lines, cultured in Matrigel or colla-
gen for 48  h. b Relative percentage of CD81 + beads derived from 
human CRC organoids. Pairwise experiments were carried out and 
in each experiment collagen data normalized to cell number was 
compared to the normalized Matrigel-derived data (n = 4). The per-
centage of positive beads in Matrigel and collagen cultures without 
organoids was < 1%. c Quantification of active caspase-3 + apoptotic 
cells in CRC organoids. Images were taken from whole-mount stain-
ings and the proportion of positive cells was counted. Ten organoids 
were counted from each CRC organoid line and their average was 
then used for evaluation. Scale bars: 20 µm. Paired (b) or unpaired (c) 
t tests were done
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To test whether CRC organoid-derived EVs have a critical 
role under unfavorable conditions, we compared normoxia 
and hypoxia. CRC organoid-derived EVs did not induce 
an increased fibroblast motility in wound healing assays 
in either conditions (Fig. S6c, d). Genes associated with 
fibroblast activation (ENC1, ST6GALNAC5, SEMA5A, 
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TNFSF4) [36] typically showed a transcriptional increase 
in EV-depleted CRC organoid medium-treated fibroblasts 
in hypoxic conditions; however, we detected no additional 
fibroblast activating effect when EV-enriched medium was 
added in normoxia or hypoxia (Fig. S6e).
Next, we purified EVs from human colon fibroblasts 
grown under normoxia or hypoxia and added them to CRC 
organoid-derived cells in either conditions. Interestingly, we 
observed an increased number of new organoids after EV 
treatment only when fibroblasts were cultured in hypoxia 
(Fig. 5a, c), which was not detected with EV-free superna-
tant. Importantly, EVs isolated from the acute monocytic 
leukemia patient-derived THP-1 cell line or liposomes had 
no effect (Fig. 5a, d), suggesting that the increase in orga-
noid forming efficiency is connected to fibroblast EVs. Col-
lectively, the organoid model system suggests that critical 
CRC progression factors enhance EV secretion from tumor 
cells. However, in the tumor–stroma communication, the 
stromal fibroblast-derived EVs exert a more important role 
in tumorigenesis.
Discussion
We show here that smaller EVs are detectable in the 
supernatant of 3D spheroids, independently of the culture 
matrix. We provide evidence that patient-derived orga-
noids produce EVs that can be analyzed in the culture 
supernatant, thus providing evidence that Matrigel-based 
3D organoid cultures are suitable for EV studies in CRC. 
Our data also demonstrate that critical factors in CRC 
tumorigenesis, such as Apc mutation or collagen I deposi-
tion, modify EV release from tumor organoids. Interest-
ingly, whereas fibroblast-derived EVs induced the colony 
formation ability of tumor cells in hypoxia, we could not 
detect a major effect of organoid EVs on the activation of 
fibroblasts.
So far, most studies used 2D cell cultures to unravel the 
functions of EVs in CRC and other cancers. However, the 
use of different cell lines and different culture conditions 
resulted in data with low consistency. This may be explained 
by the fact that these cell lines represent different patients, 
and during 2D culture establishing protocols, there was a 
selective advantage for the rapidly proliferating tumor cells 
that adapted to 2D conditions well. The recently developed 
3D organoid technology represents a superior model that 
maintains the cellular heterogeneity of in vivo tumors with-
out mesenchymal cells [13, 20, 31, 35]. In addition, their 
culture conditions are standardized and optimized for the 
best representation of this heterogeneity. To our knowledge, 
this is the first report of applying the 3D organoid technol-
ogy for EV analysis in CRC using direct patient-derived 
samples. In a previous study, Tauro BJ et al. used liquid 3D 
cell line-derived cultures with no significant loss in cell sur-
vival and they identified two distinct exosome populations 
[37]. Eguchi T et al. used a matrix-free 3D model system for 
cell lines [38]. Interestingly, when comparing 3D cultures, 
we detected an increased proportion of apoptotic cells in 
suspension compared to cultivation in Matrigel, although 
the size of the apoptotic population was cell line-specific. 
Thus, 3D suspension culture may be an alternative only for 
some, but not all of the cancer cell lines and patient-derived 
organoids. Interestingly, whereas in cell line-derived 3D 
cultures CD63 + EVs dominate, organoid cultures produce 
more CD81 + vesicles, thus raising the possibility that EVs 
released in cell line and organoid-based systems can be dif-
ferent. This is in line with the previous studies showing that 
EV markers differ between cell types and no universal mol-
ecule for EV detection is available [39]. However, whether 
these EVs functionally differ from each other, still needs to 
be addressed.
Different cell lines release EV subpopulations at varying 
levels and the EV subpopulations may have divergent func-
tions due to their different biogenesis and molecular cargo 
[40–42]. Although the molecular composition of EVs is 
influenced by the posttranslational modifications of proteins 
[43], other mechanisms are much less well known. Since 
there are no genetic models to block the release of only one 
specific EV subpopulation, recently, EVs have been sug-
gested to be classified based on size (e.g., small and large 
EV categories) [6]. Importantly, in contrast to 2D and 3D 
suspension cultures, supernatants of colonies and organoids 
in 3D matrix contain preferentially smaller EVs.
Fig. 4  Mouse intestinal organoids release a higher amount of EVs 
after Apc mutation. a Morphology of mouse intestinal organoids 
before (left and middle images) and after Apc mutation (right panel). 
Note that without R-Spondin1 (RSpo) only Apc-mutant (right panel), 
but not wild-type (WT, middle panel) organoids survive. Scale bars: 
100  µm. b Percentage of CD81 + beads, normalized to equal cell 
numbers (flow cytometry). Anti-CD81-coated beads were incubated 
in the supernatant of WT or Apc-mutant (sgApc) cultures and EV-
bound beads were detected by anti-CD81 (n = 4). c Confocal micro-
scopic images of WT, Apc-mutant and WT organoids treated with 
Wnt3a (100 ng/ml for 3 days, scale bars: 50 µm). The percentage of 
Ki67+ (d) or Mucin2 + cells (e) in the presence of Apc mutation or 
the indicated treatments, counted in confocal microscopic images 
(n = 8–10). In case of organoids treated with CHIR99021 (3 µM for 
3 days) that activates the Wnt pathway, results are compared to con-
trol samples maintained in 1% DMSO. f Relative RNA levels of the 
indicated genes (qPCR, n = 5). g Relative percentage of CD81 + beads 
(flow cytometry). In each case, results were normalized to cell num-
ber and they were then compared to the control untreated sample. For 
all measurements, the Matrigel control samples without organoids 
gave < 1% positivity for CD81 + beads (n = 5). h Percentage of active 
caspase-3 + cells after Apc mutation and the indicated treatments, 
counted on confocal microscopic images (n = 10). Student’s paired 
(F middle panel) or unpaired t test (b and f left and right panels), 
Kruskal–Wallis test with Dunn post hoc test (d, e, h left panels, g) or 
Mann–Whitney U tests (d, e, h right panels) were used
◂
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Although in vivo and in vitro studies show an elevated 
EV release from tumor cells [11, 44, 45], factors responsible 
for this effect have been addressed only in a few reports. For 
example, the presence of p53 is critical for the increased EV 
release after DNA damage in lung cancer cell lines [46]. 
KRAS mutations represent another important genetic event 
in many cancer types; in CRC, studies on mutant KRAS 
mostly focused on changes in the molecular cargo of EVs 
and showed the selective packaging of some RNAs [47, 48]. 
Thus, our findings that EV release is induced from organoids 
after Apc mutation, a critical genetic event in CRC, and in 
the presence of collagen I, an ECM protein that often accu-
mulates in CRC, are of particular interest when EV-based 
diagnostic tools are developed to monitor tumor-derived 
EVs from body fluids. Furthermore, our studies suggest 
that Apc mutation exerts its enhancing effect on EV release 
via inducing the Wnt pathway. Wnt activity and cell pro-
liferation are closely connected in the intestinal epithelium 
and intestinal adenomas. However, since all our data are 
normalized to cell number, the increased cell number can-
not explain the higher EV release. Of note, further stud-
ies are required to determine whether the higher EV secre-
tion is a direct effect of the Wnt pathway or it reflects the 
Wnt-induced changes in the relative ratios of different cell 
populations.
Stromal fibroblasts critically contribute to CRC tumo-
rigenesis by producing hepatocyte growth factor (HGF) to 
establish the cancer stem cell phenotype [49] and TGFβ 
treatment activates fibroblasts to enhance metastasis, par-
tially via IL-11 [5]. Furthermore, there is a strong cor-
relation between the stromal gene expression pattern and 
the disease outcome in CRC [50]. CRC cell-derived EVs 
Fig. 5  EVs from hypoxic fibroblasts induce the organoid forma-
tion of CRC cells. Medium from Thp-1 cells or fibroblasts (Fibr) 
were collected after 2  days, ultracentrifuged and the supernatant 
(S) or the pellet (P) were added. Note that in case of cell cultures, 
the pellet contains the EVs. As control, medium was applied. Sam-
ples from normoxic (a) or hypoxic conditions (b, c) were then tested 
using CRC organoid cells and colony formation was counted as read-
out either in normoxia (a, b) or hypoxia (c) after 4 days. Three CRC 
organoid lines were tested twice (***p < 0.005 for all three data sets 
with Kruskal–Wallis test. Dunn post hoc test was carried out and 
results from pairwise comparisons are shown only for the indicated 
comparison). d Number of new organoids after treatment with 1 × 
 1011 liposomes. In each experiment, results were compared to the 
untreated control. Note that liposomes were incubated in normoxia 
or hypoxia for 2 days, added to CRC organoid cells and the organoid 
formation was tested in normoxia or hypoxia, respectively
2475Extracellular vesicle release from intestinal organoids is modulated by Apc mutation and…
1 3
polarize tumor-associated macrophages by miR-145 [51], 
thus showing that these EVs may be active in some cell 
populations. Interestingly, in contrast to breast cancer, 
where cancer cell-derived EVs mediate the stromal mobi-
lization of Wnt–planar cell polarity signaling leading to 
tumor cell migration [52], we could not detect a marked 
effect of organoid-derived EVs on fibroblast activation in 
CRC. However, fibroblast EVs had an enhancing effect 
on CRC organoid colony-forming ability in hypoxia. The 
importance of EVs of fibroblast origin is further supported 
by Hu et al. [53], who found that fibroblast-derived EVs 
contribute to chemoresistance in CRC. In another study, 
cancer-associated fibroblast EVs supported pancreatic can-
cer aggressiveness only in hypoxia and lipid starvation 
[54], thus showing that EVs may have a function only 
under unfavorable conditions in some cancer models.
In conclusion, using the novel 3D organoid model, we 
present evidence that critical factors in CRC initiation 
and progression, such as Apc mutation, induce EV release 
from tumor cells. Furthermore, fibroblast-derived EVs 
enhance the colony-forming ability of CRC organoid cells 
in hypoxia. Our results highlight the power of the organoid 
technology in EV characterization studies and they provide 
clues for using EVs as diagnostic markers in CRC.
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